2篇
您的检索式：作者名="Xuanlan Chen"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Calculation analysis of ther- mal loss and temperature field of in-wheel motor in mi- cro-electric vehicle 显示文摘 | Qiping Chen Xuanlan Yang | 2014 | Journal of Mechanical Science and Technology2014，28，8： | 1 |
| 2 | Arginine vasopressin induces ferroptosis to promote heart failure via activation of the V1aR/CaN/NFATC3 pathway显示文摘Arginine vasopressin(AVP)is a key contributor to heart failure(HF),but the underlying mechanisms remain unclear.In the present study,a mouse model of HF and human cardiomyocyte(HCM)cells treated with dDAVP are generated in vivo and in vitro,respectively.Hematoxylin and eosin(HE)staining is used to evaluate the morphological changes in the myocardial tissues.A colorimetric method is used to measure the iron concentration,Fe^(2+)concentration and malondialdehyde(MDA)level.Western blot analysis is used to examine the protein levels of the V1a receptor(V1aR),calcineurin(CaN),nuclear factor of activated T cells isoform C3(NFATC3),glutathione peroxidase 4(GPX4)and acyl-CoA synthase long chain family member 4(ACSL4).Immunoprecipitation(IP)and luciferase reporter assays are performed to determine the interaction between NFATC3 and ACSL4.Both in vivo and in vitro experiments reveal that the V1aR-CaN-NFATC3 signaling pathway and ferroptosis are upregulated in HFs,which are verified by the elevated protein levels of V1aR,CaN,NFATC3 and ACSL4;reduced GPX4 protein level;and enhanced Fe^(2+)and MDA levels.We further find that inhibiting NFATC3 by suppressing the V1aR/CaN/NFATC3 pathway via V1aR/CaN inhibitors or sh-NFATC3 not only alleviates HF but also inhibits AVP-induced ferroptosis.Mechanistically,sh-NFATC3 significantly reverses the increase in AVP-induced ACSL4 protein level,Fe^(^(2+))concentration,and MDA level by directly interacting with ACSL4.Our results demonstrate that AVP enhances ACSL4 expression by activating the V1aR/CaN/NFATC3 pathway to induce ferroptosis,thus contributing to HF.This study may lead to the proposal of a novel therapeutic strategy for HF. | Zhiyong Wu Hua Jiang Qiulin Yin Zhifeng Zhang Xuanlan Chen | 2024 | Acta Biochimica et Biophysica Sinica2024，56，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员